Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To evaluate genetic factors associated with MTX metabolism, we performed a genome-wide association study in 447 ALL cases from the Nordic Society for Pediatric Haematology and Oncology ALL2008 study, validating results in an independent set of 196 patients. The intergenic single-nucleotide polymorphism rs1382539, located in a regulatory element of DHFR, was associated with increased levels of short-chain MTX polyglutamates (P = 1.1 × 10-8) related to suppression of enhancer activity, whereas rs35789560 in FPGS (p.R466C, P = 5.6 × 10-9) was associated with decreased levels of long-chain MTX polyglutamates through reduced catalytic activity. Furthermore, the FPGS variant was linked with increased relapse risk (P = .044). These findings show a genetic basis for interpatient variability in MTX response and could be used to improve future dosing algorithms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472715 | PMC |
| http://dx.doi.org/10.1182/blood.2020005064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Split vs single-dose oral methotrexate in rheumatoid arthritis: a randomized controlled trial (SMART study).
Clin Rheumatol
August 2025
Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.
Objective: Pharmacokinetic evidence suggests split dose of oral methotrexate increases bioavailability, but unproven to improve efficacy. Thus, we planned to compare clinical response of split vs single-dose oral methotrexate in rheumatoid arthritis (RA).
Methods: This pragmatic, open-label (blinded assessor) randomized controlled trial was conducted across six university hospitals in India and enrolled patients with seropositive RA with active disease (TJC ≥ 4 and SJC ≥ 2).
Quantitation of methotrexate polyglutamates in red blood cells and application in patients with Crohn's disease.
Transl Clin Pharmacol
June 2025
Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.
Methotrexate (MTX), a folate antagonist, is commonly administered at low doses for the treatment of Crohn's disease (CD). Anti-inflammatory effects of MTX are facilitated by its intracellular conversion to MTX polyglutamates (MTX-PGs). Because plasma-based monitoring of therapeutic response does not accurately reflect the therapeutic efficacy of MTX, quantifying intracellular MTX-PGs, potential biomarkers of the MTX response, is crucial.
View Article and Find Full Text PDFA new kind of polystyrene/polyethyleneimine nanofibres coordinated with palladium for fast and efficient extraction of methotrexate and its polyglutamate metabolites in different matrices.
RSC Adv
May 2025
Key Laboratory of Child Development and Learning Science (Ministry of Education), School of Biological Science & Medical Engineering, Southeast University Nanjing 210096 China
Methotrexate (MTX) is a drug that has long been used in high doses as an anti-cancer drug and lately in low doses as a treatment for autoimmune diseases. It is necessary to be determined in various matrices because the drug has a narrow therapeutic range and a high persistence in the environment. Since MTX and its polyglutamate metabolites (MTXPGs) have strong polarity and the potential to be converted during sample processing, rapid and efficient extraction of these targets has provided technical challenges for development of analytical methods for them.
View Article and Find Full Text PDFHydroxychloroquine increases the exposure of methotrexate in plasma and red blood cells: a pharmacokinetic interaction study in rats in vivo.
Front Pharmacol
April 2025
Department of Pharmacy, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
Introduction: Hydroxychloroquine (HCQ) has been demonstrated to be potential to enhance the therapeutic efficacy of methotrexate (MTX) for rheumatoid arthritis (RA) patients. However, the pharmacokinetics (PK) alterations and underlying mechanisms differentiating MTX-HCQ combination therapy from MTX monotherapy remain uncharted.
Methods: Thirty-three Sprague-Dawley rats were divided into single-dose and multiple-dose groups, with each group further randomized into an MTX monotherapy group an Hydroxychloroquine monotherapy group (HTG), and an MTX-HCQ combination therapy group Blood samples were collected at various time points before and after dosing to determine drug concentrations in plasma and red blood cells (RBC).
Unique methotrexate polyglutamates distributions in peripheral blood mononuclear cells of rheumatoid arthritis patients: Development and validation of a UPLC-MS/MS method.
J Pharm Biomed Anal
September 2025
Laboratory of Specialized Diagnostics & Research, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam, the Netherlands. Electronic address:
Methotrexate is pivotal in treating immune-mediated inflammatory diseases. Intracellularly, methotrexate is metabolized to methotrexate-polyglutamates (MTX-PG), comprising up to six additional glutamate moieties, crucial for cellular retention and therapeutic efficacy. Hitherto, quantification of MTX-PG in peripheral blood mononuclear cells (PBMCs) from methotrexate-treated patients was challenging due to their low abundance in blood and matrix effects.
View Article and Find Full Text PDF